Clinical Trial

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-12-30; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2023-07-26
Trial Details
NCT Number NCT04691817
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Genentech, Inc.
Conditions Lung Cancer, Nonsmall Cell
Enrollment 28 participants
Start Date 2023-07-25
Primary Completion 2026-12 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-07